1 - 3 of 3
Dr. Green’s long-term goal is to elucidate the sources of DNA damage in childhood leukemia in order to develop better therapies and ultimately improve outcomes. She specifically studies the intersection of immune responses to viral infection and genome instability, working closely with virologists, oncologists, and geneticists at Children’s Hospital of Philadelphia, Penn, and nationwide.
Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.